Research progress of sodium-glucose cotransporter 2 inhibitor in non-alcoholic fatty liver disease

Research progress of sodium-glucose cotransporter 2 inhibitor in non-alcoholic fatty liver disease

Sodium-glucose cotransporter 2 inhibitor (SGLT-2i) is a new type of anti-diabetes drug. Clinical studies have shown that SGLT-2i plays a beneficial role in the treatment of patients with non-alcoholic fatty liver disease (NAFLD). SGLT-2i can reduce hepatic endoplasmic reticulum stress, regulate infl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ji chu yi xue yu lin chuang = Jichu yixue yu linchuang = Basic medical sciences and clinics 2023-10, Vol.43 (10), p.1594-1598
1. Verfasser: HUANG Lichenlu, ZHANG Jiarui, ZHENG Yongqin, HE Jundong
Format: Artikel
Sprache:chi
Schlagworte:
non-alcoholic fatty liver disease|sodium-glucose cotransporter 2 inhibitor
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Sodium-glucose cotransporter 2 inhibitor (SGLT-2i) is a new type of anti-diabetes drug. Clinical studies have shown that SGLT-2i plays a beneficial role in the treatment of patients with non-alcoholic fatty liver disease (NAFLD). SGLT-2i can reduce hepatic endoplasmic reticulum stress, regulate inflammatory reaction, improve liver fibrosis and increase hepatocyte autophagy to alleviate symptoms of NAFLD patients.
ISSN:1001-6325
DOI:10.16352/j.issn.1001-6325.2023.10.1594